PatientsVille.com Logo

MUSCULAR WEAKNESS and ZOCOR

PatientsVille

MUSCULAR WEAKNESS Symptoms and Causes

Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest.

Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker.

Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests.

With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps.

Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for MUSCULAR WEAKNESS

MUSCULAR WEAKNESS treatment research studies

ZOCOR clinical trials, surveys and public health registries


Find Drug Side Effect reports



ZOCOR Side Effects

Rhabdomyolysis (1045)
Myalgia (844)
Blood Creatine Phosphokinase Increased (494)
Asthenia (430)
Muscular Weakness (393)
Renal Failure Acute (366)
Pain In Extremity (328)
Arthralgia (302)
Muscle Spasms (284)
Fatigue (263)
Myopathy (253)
Renal Failure (231)
Pain (228)
Dyspnoea (220)
Myocardial Infarction (202)
Myositis (201)
Nausea (196)
Alanine Aminotransferase Increased (184)
Chest Pain (179)
Dizziness (178)
Fall (128)
Aspartate Aminotransferase Increased (127)
Malaise (122)
Cerebrovascular Accident (120)
Diarrhoea (119)
Headache (104)
Back Pain (101)
Liver Function Test Abnormal (101)
Depression (100)
Abdominal Pain (95)
Gait Disturbance (93)
Blood Creatinine Increased (93)
Anxiety (92)
Abasia (91)
Vomiting (87)
Amnesia (86)
Abdominal Pain Upper (79)
Anaemia (78)
Coronary Artery Disease (76)
Insomnia (75)
Cardiac Failure Congestive (74)
Weight Decreased (73)
Dehydration (72)
Pyrexia (71)
Confusional State (70)
Paraesthesia (70)
Hypertension (69)
Pneumonia (69)
Rash (68)
Cardiac Disorder (67)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

How long does it take to get back to normal after taking Zocor. I had a major problem in November 2008 and it is now May 2009 and I am still having problems and testing. It has cost me a fortune and they still say it is not Zocor but I still believe

I am asking, does Levaxin a thyroid med. and Zantac antiacid, is it OK to take those at the same time

I have a frozen diagfram and shrinking lung. It affects my breathing and energy. Could this possibly be caused by Zocor as I was told by someone who also has this condition. I also have lots of muscle pain daily.&nbs

Lip swelling, acute.

Urinary retention Is there a correlation between this and using a statin. Had this problem shortly after starting a simvistatin routine.

Zocor 40 mg, Typical gout experience 2 times a month, treatable with fluids and diet. Some use of colchicine. Within a week of using Zocor experienced gout over an extended period of time. Basically 6 weeks straight. Taking Zocor at night and exp

Zocor 40mg. Since I started taking have had rotator repair, frozen shoulder same shoulder, tarsal tunnel in my ankle. Surgery and now frozen shoulder other shoulder that my doc wants to operate on

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

<strong></strong><span style='color: #ffa500;'>I am experiencing severe muscular <span style='color: #0000ff;'>pain/muscle tighteningin the diaphragm and sometimes &

<strong>I am on Cipralex now for about 2-3 months -10mg in the morning for depression, and now am experiencing chronic muscle weakness, chronic pain in both wrists and left hip, chronic fatigue, nausea, constant dizziness, tremors/shaky, restle

2 patients given thiocolchicoside reported of muscular stiffness,uneasiness,insomnia,breathlessness and feeling of restlessness, 2 out of 5 patients have reported such experiences after consuming thiocolchicoside.i strongly recommend to withdraw this

Afeccion cardiaca,pues a pesar de hacer ejercicio se me bloquearon las arterias,por mucho colesterol y tuvieron que hacerme un cateterismo, tengo once aos de que me detectaron la enfermedad. He perdido masa muscular pero nado ycamino dos o tres ve

After 18 months, great fatigue and muscular pain. Is this due to Intragam? consultant thinks I'm being fussy

After a 1 week course of Trimethoprim 200mg. I developed mild thrush on day3, muscle weakness for 1 day on the day after completion of the course and, 3 days after completion generalised urticaria. Not sure if this is delayed sensitivity but I assu

After finnishing the dose for Artequin I started feeling, body twitching, weakness,dizzness, body cramps, headache, neck pain, sore joints and now am at my sixth day after the dose and still experiencing the side effects..

After my first injection on Friday three weeks ago I experienced numbness and weakness Sunday night after injection along with a fever and night sweats. Went back to doctor on Tuesday and had an ultrasound to see if blockages or blood clots everythin

After takin tablets, i am feelimg somewhat uneasyness, feeling weakness, food intake is reduced

MUSCULAR WEAKNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: Prostate Carcinoma
Interventions: Drug: Metformin;   Drug: Simvastatin
Outcome Measures: Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.;   Time to protocol-specified event for men treated with the combination of metformin plus simvastatin.;   Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin.;   Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
2 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
Outcome Measures: Safety of simvastatin in the treatment of LAM-S and LAM-TS patients on a stable (for at least 3 months) dose of sirolimus or everolimus.;   FEV1, FVC, DLCO, VEGF-D, and QOL; signs of clinical benefit.
3 Not yet recruiting Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Conditions: Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
Outcome Measures: Change in echocardiographic Global Longitudinal Strain (GLS);   Number of participants with adverse events as a measure of safety and tolerability;   Recurrence free survival (RFS) with concurrent simvastatin
4 Unknown  Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: Simvastatin
Outcome Measure: Progression free survival
5 Recruiting Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia
Interventions: Drug: Fenofibrate;   Drug: Simvastatin
Outcome Measures: Percentage change from baseline in triglycerides (TG) at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12;   Percentage changes from baseline in apoB/apoA1 ratio at week 12;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12;   Percentage changes from baseline in uric acid at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52;   Percentage changes from baseline in apoB/apoA1 ratio at week 52;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52;   Percentage changes from baseline in uric acid at week 52
6 Recruiting The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Condition: Asthma
Interventions: Drug: Simvastatin;   Drug: B1-6-12
Outcome Measures: Sputum eosinophils;   Phosphorylated p38 MAPK in sputum cells
7 Recruiting Stroke Treatment With Acute Reperfusion and Simvastatin
Condition: Stroke, Acute
Intervention: Drug: Simvastatin
Outcome Measures: The primary outcome of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.;   The secondary outcome of this study is to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.
8 Recruiting Simvastatin Addition for Patients With Recent-onset Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder;   Psychosis NOS
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Change in Positive And Negative Syndrome Scale (PANSS) total score;   Change in PANSS positive, negative and general psychopathology scale scores;   Change in Global Assessment of functioning scale (GAF) score;   Change in cognitive functioning;   Presence and severity of metabolic syndrome;   Change in presence and severity of movement disorders using validated scales
9 Recruiting Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
Condition: Rhinosinusitis
Intervention: Drug: SIMVASTATIN
Outcome Measures: Sino-Nasal symptomatology;   Bacterial culture;   Assessemt of liver and kidney functions;   RNA measurement of inflammatory biomarkers;   Sinus-Specific Quality of Life (22 questions Sino-nasal outcome test; SNOT-22);   Aspect of sinus mucosa aspect assessed by sinus endoscopy
10 Recruiting Effects of Simvastatin on Biomarkers
Condition: Alzheimer's Disease
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Cerebral Spinal Fluid Biomarker measurements;   Measures of inflammation or oxidative stress in cerebral spinal fluid.
11 Not yet recruiting The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia
Condition: Choroideremia
Intervention: Drug: Simvastatin
Outcome Measures: Full-field scotopic threshold;   Microperimetry, OCT, fundus autofluorescence, ERG, VA
12 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
Outcome Measures: the simvastatin can alleviate pulmonary hypertension;   pulmonary pressure;   simvastatin can highten the perioperative and long term survaval rate and the living quality
13 Recruiting Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Simvastatin
Outcome Measures: Vaso-occlusive pain events;   Correlation of plasma biomarkers with clinical measures of vaso-occlusive pain;   Clinical safety of simvastatin
14 Unknown  Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.
Conditions: Diabetes Mellitus;   Hypertension
Interventions: Drug: atrorvastatin 10mg;   Drug: simvastatin 40mg
Outcome Measures: Reduction in oxLDL levels;   Reduction in plasma malondialdehydes and urine isoprostanes;   Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor
15 Unknown  Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)
Conditions: Dyslipidemia;   Atherosclerosis
Interventions: Drug: simvastatin;   Drug: Nicotinic Acid
Outcome Measures: change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE);   changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a).
16 Recruiting Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Condition: Bipolar Disorder
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measure: Change in MADRS (4 weeks)
17 Unknown  Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Conditions: Cystic Fibrosis;   Anti Inflammatory Non-Steroidal;   Neutrophils
Interventions: Drug: Pioglitazone;   Drug: Simvastatin;   Drug: Ibuprofen
Outcome Measure: Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique
18 Recruiting Simvastatin for mTBI
Condition: TBI-Traumatic Brain Injury
Interventions: Drug: simvastatin;   Drug: placebo
Outcome Measures: cerebrospinal fluid (CSF) tau concentration;   Concentration of cerebrospinal fluid (CSF) Brain-derived neurotrophic factor (BDNF)
19 Recruiting Sarilumab Effect on the Pharmacokinetics of Simvastatin
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Drug: simvastatin
Outcome Measures: Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for simvastatin;   Assessment of PK parameters - maximum concentration (Cmax), time to maximum concentration (tmax), and terminal half-life associated with the terminal slope (t1/2z) for simvastatin;   Assessment of PK parameters - Cmax, AUClast, AUC, tmax, t1/2z for simvastatin acid;   Number of participants with adverse events
20 Recruiting Simvastatin Effect on Radiation Therapy of Brain Metastases
Condition: Brain Metastases
Interventions: Drug: simvastatin in addition to radiation therapy;   Radiation: radiation therapy
Outcome Measures: a- Response rate;   progression free and overall survival;   adverse effects